Eledon Pharmaceuticals Inc (ELDN)

$2.42 -0.12 (-4.72%)
Market Cap 155.09M
Revenue (ttm) 0.00
Net Income (ttm) -36.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 677,500
Avg Vol 784,058
Day's Range N/A - N/A
Shares Out 59.88M
Stochastic %K 3%
Beta -0.12
Analysts Strong Sell
Price Target $9.50

Company Profile

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 238 8090
Website: eledon.com
Address:
19800 MacArthur Boulevard, Suite 250, Irvine, United States
Veraton
Veraton Sep. 12 at 10:51 PM
$ELDN bullshit movement!!! This is a done deal! 😺
0 · Reply
Ontherag
Ontherag Sep. 12 at 8:47 PM
$ELDN lol Classic
0 · Reply
jshlam
jshlam Sep. 12 at 4:43 PM
$ELDN time to load
0 · Reply
Ontherag
Ontherag Sep. 11 at 9:35 PM
$ELDN Algos are dumb, ruining the market, oh well
0 · Reply
SlayQueenOfCalls
SlayQueenOfCalls Sep. 10 at 2:48 PM
$ELDN nope! But we need volume ya?
0 · Reply
MrCodyHUN
MrCodyHUN Sep. 9 at 1:08 PM
$ELDN +4% in the pre-market? Will this evaporate rightaway when the market opens?
0 · Reply
Ontherag
Ontherag Sep. 9 at 11:39 AM
$ELDN https://egenesisbio.com/press-releases/egenesis-announces-ind-clearance-for-egen-2784-in-kidney-transplant-and-landmark-patient-updates-in-ongoing-expanded-access-study/
1 · Reply
ErnieWorthing84
ErnieWorthing84 Sep. 8 at 10:38 PM
$ELDN https://apnews.com/article/pig-kidney-xenotransplant-genetic-editing-egenesis-f6ac63e72d65428b030d78fdb44295e8
1 · Reply
MrCodyHUN
MrCodyHUN Sep. 8 at 5:49 PM
$ELDN
0 · Reply
MrCodyHUN
MrCodyHUN Sep. 8 at 6:55 AM
$ELDN New restistance levels: 2.83, 2.95 & 3.06.
0 · Reply
Latest News on ELDN
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Aug 29, 2025, 7:00 AM EDT - 14 days ago

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Aug 14, 2025, 4:20 PM EDT - 4 weeks ago

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Aug 6, 2025, 4:01 PM EDT - 5 weeks ago

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Jul 30, 2025, 4:05 PM EDT - 6 weeks ago

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Jul 17, 2025, 4:01 PM EDT - 2 months ago

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

Jun 25, 2025, 4:01 PM EDT - 2 months ago

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

May 14, 2025, 4:01 PM EDT - 4 months ago

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

Undercovered Dozen: Gevo, Eledon, Dorian, Iridium +

May 6, 2025, 1:15 PM EDT - 4 months ago

Undercovered Dozen: Gevo, Eledon, Dorian, Iridium +

GEVO IRDM LPG

Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet

May 3, 2025, 8:15 AM EDT - 4 months ago

Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Mar 20, 2025, 4:01 PM EDT - 6 months ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Mar 4, 2025, 4:05 PM EST - 6 months ago

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Feb 7, 2025, 10:00 AM EST - 7 months ago

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 4:05 PM EST - 8 months ago

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business

Jan 28, 2025, 11:27 AM EST - 8 months ago

Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Jan 13, 2025, 7:00 AM EST - 8 months ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 12, 2024, 4:01 PM EST - 10 months ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29, 2024, 3:51 PM EDT - 11 months ago

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Oct 29, 2024, 7:46 AM EDT - 11 months ago

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Oct 29, 2024, 7:45 AM EDT - 11 months ago

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Sep 11, 2024, 4:05 PM EDT - 1 year ago

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Aug 14, 2024, 5:21 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:30 AM EDT - 1 year ago

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

May 9, 2024, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

May 7, 2024, 7:05 AM EDT - 1 year ago

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Mar 28, 2024, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Mar 25, 2024, 4:56 PM EDT - 1 year ago

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Mar 21, 2024, 10:31 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 13, 2024, 7:01 PM EST - 1 year ago

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Jan 4, 2024, 4:40 PM EST - 1 year ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

Nov 29, 2023, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Nov 9, 2023, 4:01 PM EST - 2 years ago

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Nov 8, 2023, 4:05 PM EST - 2 years ago

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Nov 2, 2023, 9:05 AM EDT - 2 years ago

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Oct 13, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

Oct 2, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 20, 2023, 4:05 PM EDT - 2 years ago

Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results

Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference

Eledon Pharmaceuticals, Inc. (ELDN) Q1 2023 Earnings Call Transcript

May 12, 2023, 1:03 PM EDT - 2 years ago

Eledon Pharmaceuticals, Inc. (ELDN) Q1 2023 Earnings Call Transcript

Eledon Pharmaceuticals: Disrupting The Kidney Transplantation Landscape

May 10, 2023, 2:45 PM EDT - 2 years ago

Eledon Pharmaceuticals: Disrupting The Kidney Transplantation Landscape

Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology

Mar 31, 2023, 6:00 AM EDT - 2 years ago

Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology

Eledon Pharmaceuticals, Inc. (ELDN) Q4 2022 Earnings Call Transcript

Mar 30, 2023, 8:28 PM EDT - 2 years ago

Eledon Pharmaceuticals, Inc. (ELDN) Q4 2022 Earnings Call Transcript

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results

Mar 30, 2023, 4:01 PM EDT - 2 years ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results

Veraton
Veraton Sep. 12 at 10:51 PM
$ELDN bullshit movement!!! This is a done deal! 😺
0 · Reply
Ontherag
Ontherag Sep. 12 at 8:47 PM
$ELDN lol Classic
0 · Reply
jshlam
jshlam Sep. 12 at 4:43 PM
$ELDN time to load
0 · Reply
Ontherag
Ontherag Sep. 11 at 9:35 PM
$ELDN Algos are dumb, ruining the market, oh well
0 · Reply
SlayQueenOfCalls
SlayQueenOfCalls Sep. 10 at 2:48 PM
$ELDN nope! But we need volume ya?
0 · Reply
MrCodyHUN
MrCodyHUN Sep. 9 at 1:08 PM
$ELDN +4% in the pre-market? Will this evaporate rightaway when the market opens?
0 · Reply
Ontherag
Ontherag Sep. 9 at 11:39 AM
$ELDN https://egenesisbio.com/press-releases/egenesis-announces-ind-clearance-for-egen-2784-in-kidney-transplant-and-landmark-patient-updates-in-ongoing-expanded-access-study/
1 · Reply
ErnieWorthing84
ErnieWorthing84 Sep. 8 at 10:38 PM
$ELDN https://apnews.com/article/pig-kidney-xenotransplant-genetic-editing-egenesis-f6ac63e72d65428b030d78fdb44295e8
1 · Reply
MrCodyHUN
MrCodyHUN Sep. 8 at 5:49 PM
$ELDN
0 · Reply
MrCodyHUN
MrCodyHUN Sep. 8 at 6:55 AM
$ELDN New restistance levels: 2.83, 2.95 & 3.06.
0 · Reply
ErnieWorthing84
ErnieWorthing84 Sep. 8 at 1:44 AM
$ELDN https://www.renalandurologynews.com/features/xenotransplantation-kidney/
0 · Reply
Veraton
Veraton Sep. 5 at 3:57 PM
$ELDN What's going on... Volume picking up fast... If this company really can break the balls for ALS.... Godspeed for patients and future generations suffering from this dreadful disease....
1 · Reply
ErnieWorthing84
ErnieWorthing84 Sep. 5 at 3:49 PM
$ELDN Putin and Xi buying
0 · Reply
Ontherag
Ontherag Sep. 4 at 11:18 PM
$ELDN Added
0 · Reply
ErnieWorthing84
ErnieWorthing84 Sep. 4 at 8:45 PM
$ELDN Count it https://www.reuters.com/business/media-telecom/hot-mic-picks-up-putin-xi-discussing-organ-transplants-immortality-2025-09-03/
1 · Reply
MrCodyHUN
MrCodyHUN Sep. 4 at 1:32 PM
$ELDN The daily bollinger bands are basically about to pop
0 · Reply
MrCodyHUN
MrCodyHUN Sep. 4 at 7:17 AM
$ELDN https://finance.yahoo.com/news/eledon-pharmaceuticals-participate-cantor-global-110000276.html
0 · Reply
Ontherag
Ontherag Sep. 3 at 10:30 PM
$ELDN 850k
0 · Reply
JarvisFlow
JarvisFlow Sep. 2 at 11:30 AM
HC Wainwright & Co. updates rating for Eledon Pharmaceuticals ( $ELDN ) to Buy, target set at 9.
0 · Reply
MrCodyHUN
MrCodyHUN Aug. 26 at 2:56 PM
$ELDN https://www.youtube.com/watch?v=Gp7TfLKUXxE&list=RDGp7TfLKUXxE&start_radio=1
0 · Reply
MrCodyHUN
MrCodyHUN Aug. 26 at 2:35 PM
$ELDN Resistance at 2.65, 2.73 and 2.79
0 · Reply
SlayQueenOfCalls
SlayQueenOfCalls Aug. 25 at 1:58 PM
$ELDN $3 sell price on 7.50 calls for February wow.
0 · Reply